Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Colorectal cancer (CRC) is the fourth most common cancer and the second leading cause of cancer death among men and women in the United States (US). The lifetime risk of colorectal cancer in both men and women in the US is approximately 6%. About 93% of colorectal cancer (CRC) diagnoses are in patients older than 50 years (Siegel 2014). Randomized controlled trials show that screening for CRC significantly decreases CRC incidence and mortality (Schoen 2012, Atkin 2010, Mandel 1999, Mandel 2000). CRC screening has received a Grade A recommendation from the US Preventive Services Task Force.
In the U.S., colonoscopy is the most utilized screening modality for CRC. On a population basis, screening rates, which were around 40-50%, have now increased to 65%, and a goal to increase to 80% compliance is being promoted (CDC 2011, CDC 2013, Meester 2015).
Adenomatous polyps are the acknowledged precursors of colorectal cancer. Identification and removal of adenomas is the mechanism by which screening is effective in reducing CRC incidence and subsequent mortality. "Advanced" adenomas are adenomas which are greater than or equal to 1 cm, or have a "villous" component (tubulovillous or villous), or have foci of high grade dysplasia. Advanced adenomas are associated with increased long-term risk of cancer, even years after colonoscopy (Click 2018). The prevalence of advanced adenomas at screening colonoscopy is 5-10% (Ferlitsch 2011, Imperiale 2014). Non-advanced adenomas are adenomas greater than 1 cm with neither villous components nor high grade dysplasia. Non-advanced adenomas are much more common than advanced adenomas, present in around 30% of colonoscopy exams (Ferlitsch 2011, Imperiale 2014).
After detection of adenomas, patients are advised to return periodically for surveillance colonoscopy. Patients with 1-2 non-advanced adenomas are recommended by guidelines to return in 5 - 10 years for follow-up surveillance colonoscopy (Lieberman 2012). However, there are no guidelines on how to triage individuals to 5 as opposed to 10 years. Furthermore, there is limited evidence supporting the effectiveness of surveillance colonoscopy in reducing CRC incidence. A retrospective study in patients with advanced adenomas demonstrated benefit (Atkin 2017), but the study was not randomized and did not include patients with 1-2 non-advanced adenomas. The only randomized trial of surveillance colonoscopy was reported in the early 1990's, when participants were randomized to 3 vs. 1- and 3- year surveillance (Winawer 1993). No difference in advanced adenoma detection was observed when comparing participants examined at the two screening intervals, and as a result, guidelines were modified with participants advised to return every 3 years after adenomatous polyp detection. The recommended interval for non-advanced adenomas was gradually lengthened to the current standard, but there is no randomized, controlled data to support that interval. Furthermore, observational data of surveillance colonoscopy practice in the U.S. demonstrate that recommended intervals are often not adhered to, and individuals return for repeat testing well ahead of guideline recommendations (Schoen 2010, Lieberman 2014).
Furthermore, if anything, retrospective, natural history studies of non-advanced adenomas do not support the association of non-advanced adenoma with a higher risk of subsequent colorectal cancer (Atkin 1992, Spencer 1984, Loberg 2014). For example, in a classic study from the United Kingdom, patients with small rectosigmoid adenomas, even if multiple, did not have an increased risk of CRC compared to the general population, over a 14-year mean follow-up time (Atkin 1992). In a recent observational study from Norway, participants with a low-risk adenoma followed over a median of 7.7 years (maximum 19 years) without subsequent surveillance colonoscopy, had a lower CRC mortality than the general population (Loberg 2014), implying that although the initial colonoscopy may be protective, subsequent follow-up colonoscopy was not required. More recently, several studies have reported that individuals with non-advanced adenomas do not have an increased risk of colorectal cancer compared to those with no adenomas (Click 2018, Lieberman 2019, Lee 2019).
Another recent major development affecting screening is that practitioners of colonoscopy are now recommended to monitor and insure their adenoma detection rates are high. Data from Poland (Kaminski 2010) and Kaiser Permanente in California (Corley 2014) have demonstrated that a higher adenoma detection rate (ADR) is associated with a lower long-term risk of interval CRC, or cancer occurring after colonoscopy. Our understanding of these observations is premised on the notion that leaving pre-neoplastic tissue (adenomas) in situ, (such as what occurs with a lower ADR), increases the chance that an adenoma left behind will subsequently transform into cancer. The concern over interval cancers has stimulated quality concerns about the practice of colonoscopy. Guidelines for a recommended ADR at screening colonoscopy are rising, from the initial targets of 15% in women and 25% in men (Lieberman 2012) to 20% in women and 30% in men or 25% overall. ADRs in clinical studies are now commonly over 30% and some practitioners report rates exceeding 50%. However, adenomas that are detected when the ADR is high or as it increases over time are generally small, non-advanced adenomas.
Current clinical practice favoring colonoscopy-based screening with increased emphasis on detection of adenomas, most of which will turn out to be small, non-advanced adenomas, will greatly increase demand for utilization of surveillance colonoscopy exams in the coming decades. Yet, the evidence for determining the benefit, optimal timing, and recommended frequency of surveillance colonoscopy is unknown. A randomized, clinical trial to demonstrate the difference in yield between 5- or 10-year surveillance for participants with non-advanced adenoma is needed to guide clinical practice. Only a randomized trial will be authoritative enough to define good clinical practice and directly influence clinical care.
Inclusion Criteria:
Exclusion Criteria:
• Prior history of colorectal cancer or colorectal adenomas including sessile serrated polyps/adenomas excluding those found on the qualifying colonoscopy.
langerj@nrgoncology.org412-339-5300
Goodyear, Arizona 85338, United States
623-207-3000
Tucson, Arizona 85719, United States
Arroyo Grande, California 93420, United States
San Luis Obispo, California 93401, United States
Centennial, Colorado 80112, United States
Denver, Colorado 80218, United States
Englewood, Colorado 80113, United States
Englewood, Colorado 80113, United States
Englewood, Colorado 80113, United States
Littleton, Colorado 80120, United States
Lone Tree, Colorado 80124, United States
New Haven, Connecticut 06511, United States
North Haven, Connecticut 06473, United States
West Haven, Connecticut 06516, United States
Washington D.C., District of Columbia 20002, United States
Washington D.C., District of Columbia 20007, United States
Washington D.C., District of Columbia 20037, United States
Gainesville, Florida 32610, United States
Miami, Florida 33136, United States
Honolulu, Hawaii 96813, United States
Honolulu, Hawaii 96826, United States
Lihue, Hawaii 96766, United States
Mattoon, Illinois 61938, United States
Crown Point, Indiana 46307, United States
Clive, Iowa 50325, United States
Des Moines, Iowa 50314, United States
Overland Park, Kansas 66211, United States
Lexington, Kentucky 40509, United States
Mount Sterling, Kentucky 40353, United States
New Orleans, Louisiana 70112, United States
Lutherville, Maryland 21093, United States
Ann Arbor, Michigan 48109, United States
Grand Rapids, Michigan 49503, United States
Grand Rapids, Michigan 49503, United States
Norton Shores, Michigan 49444, United States
Saint Joseph, Michigan 49085, United States
Saint Joseph, Michigan 49085, United States
Crosslake, Minnesota 56442, United States
Detroit Lakes, Minnesota 56501, United States
International Falls, Minnesota 56649, United States
Maple Grove, Minnesota 55369, United States
Pequot Lakes, Minnesota 56472, United States
Pine River, Minnesota 56474, United States
Grand Island, Nebraska 68803, United States
Henderson, Nevada 89052, United States
Henderson, Nevada 89074, United States
Las Vegas, Nevada 89135, United States
Las Vegas, Nevada 89144, United States
Las Vegas, Nevada 89169, United States
New York, New York 10016, United States
New York, New York 10032, United States
Goldsboro, North Carolina 27534, United States
Jacksonville, North Carolina 28546, United States
Fargo, North Dakota 58103, United States
Centerville, Ohio 45459, United States
Cincinnati, Ohio 45219, United States
Franklin, Ohio 45005-1066, United States
West Chester, Ohio 45069, United States
Oklahoma City, Oklahoma 73104, United States
Bethlehem, Pennsylvania 18015, United States
Hazleton, Pennsylvania 18201, United States
Wilkes-Barre, Pennsylvania 18711, United States
Spartanburg, South Carolina 29307, United States
Sioux Falls, South Dakota 57117-5134, United States
Memphis, Tennessee 38120, United States
Dallas, Texas 75390, United States
Houston, Texas 77030, United States
Salt Lake City, Utah 84148, United States
Silverdale, Washington 98383, United States
Yakima, Washington 98902, United States
Appleton, Wisconsin 54915, United States
Brookfield, Wisconsin 53045, United States
Franklin, Wisconsin 53132, United States
Franklin, Wisconsin 53132, United States
Green Bay, Wisconsin 54303, United States
Janesville, Wisconsin 53548, United States
Mequon, Wisconsin 53097, United States
Milwaukee, Wisconsin 53210, United States
Milwaukee, Wisconsin 53211, United States
Milwaukee, Wisconsin 53215, United States
Oshkosh, Wisconsin 54904, United States
Racine, Wisconsin 53405, United States
Stevens Point, Wisconsin 54482, United States
Wauwatosa, Wisconsin 53226, United States
research@sncrf.org702-384-0013
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
pcarino@arizona.edu520-318-7057
800-378-9373
Research@CARTI.com501-906-4199
clinical.trials@kp.org800-398-3996
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
research@sncrf.org702-384-0013
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@commonspirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
888-798-0719
925-957-5400
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
clinical.trials@kp.org800-398-3996
ccto-office@stanford.edu650-498-7061
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
clinical.trials@kp.org800-398-3996
clinical.trials@kp.org800-398-3996
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
clinical.trials@kp.org800-398-3996
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
209-461-5257
Kpoct@kp.org877-642-4691
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
clinical.trials@kp.org800-398-3996
888-336-8262
720-848-0650
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
KPCOIHRClinicalResearch@kp.org303-817-9295
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
KPCOIHRClinicalResearch@kp.org303-817-9295
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
KPCOIHRClinicalResearch@kp.org303-817-9295
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
canceranswers@yale.edu203-785-5702
canceranswers@yale.edu203-785-5702
canceranswers@yale.edu203-785-5702
203-937-3421 ext. 2832
Charmaine.A.Mckie@kp.org240-632-4285
202-444-2223
202-741-2210
yenrique@msmc.com305-674-2625
vhabayresearch@va.gov727-398-6661
trials@cancer.ufl.edu352-273-8675
305-243-2647
jleavitt@gastrohealth.com
Yvonne.Enriquez@msmc.com305-674-2625
ga_cares@augusta.edu706-721-2388
Lorraine.OHara@hcahealthcare.com912-350-7887
Lorraine.OHara@hcahealthcare.com912-350-7887
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
618-463-5623
312-864-5204
708-226-4357
gayla.hall@ssmhealth.com618-899-1894
oncologyclinicaltrials@mhemail.org815-971-5858
844-793-0745
KUCC_Navigation@kumc.edu913-588-3671
aroland@kccop.org913-948-5588
aroland@kccop.org913-948-5588
KUCC_Navigation@kumc.edu913-588-3671
KUCC_Navigation@kumc.edu913-588-3671
620-421-4881
888-446-3729
785-270-4939
KUCC_Navigation@kumc.edu913-588-3671
316-685-2221
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
Kristi.Curtsinger@stelizabeth.com859-301-4730
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
emede1@lsuhsc.edu504-210-3539
LPost@lsuhsc.edu318-813-1404
clinicalresearch@mainehealth.org207-396-8670
Charmaine.A.Mckie@kp.org240-632-4285
Charmaine.A.Mckie@kp.org240-632-4285
Charmaine.A.Mckie@kp.org240-632-4285
Charmaine.A.Mckie@kp.org240-632-4285
Charmaine.A.Mckie@kp.org240-632-4285
877-726-5130
ctsucontact@westat.com888-823-5923
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
574-647-7370
574-647-7370
crcwm-regulatory@crcwm.org616-391-1230
616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
CancerTrials@EssentiaHealth.org218-786-3308
218-828-2880
OncologyClinicalTrialsFargo@sanfordhealth.org218-333-5000
CancerTrials@EssentiaHealth.org218-786-3308
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
218-692-1010
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
218-365-7900
CancerTrials@EssentiaHealth.org218-786-3308
218-786-3308
218-283-9431
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1572
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
612-467-2800
mmcorc@healthpartners.com952-993-1517
218-485-4481
mmcorc@healthpartners.com952-993-1517
CancerTrials@EssentiaHealth.org218-786-3308
218-568-4416
218-587-4416
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
855-776-0015
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
CancerTrials@EssentiaHealth.org218-786-3308
mmcorc@healthpartners.com952-993-1517
218-894-7870
mmcorc@healthpartners.com952-993-1517
605-312-3320
CancerTrials@EssentiaHealth.org218-786-3308
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
888-446-3729
aroland@kccop.org913-948-5588
417-269-4520
888-446-3729
LJCrockett@freemanhealth.com417-347-4030
esmeralda.carrillo@mercy.net417-556-3074
800-525-1483
clinicaltrials@lakeregional.com573-302-2768
573-458-6379
research@phelpshealth.org573-458-7504
Trisha.England2@mymlc.com816-271-7937
417-269-4520
417-269-4520
888-446-3729
Danielle.Werle@mercy.net314-525-6042
314-251-7066
636-390-1600
mccinfo@mtcancer.org406-969-6060
research@billingsclinic.org800-996-2663
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
Roster@nrgoncology.org412-339-5294
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org
702-851-4672
research@sncrf.org702-384-0013
research@sncrf.org
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
Renown-CRD@renown.org775-982-5050
research@sncrf.org702-384-0013
973-971-5900
HSC-ClinicalTrialInfo@salud.unm.edu505-925-0348
CancerTrials@nyulangone.org
cancerclinicaltrials@cumc.columbia.edu212-342-5162
jfields@cancersmoc.com919-587-9084
jfields@cancersmoc.com919-587-9084
jfields@cancersmoc.com910-587-9084
OncologyClinicalTrialsFargo@sanfordhealth.org701-323-5760
CancerTrials@EssentiaHealth.org218-786-3308
701-234-6161
605-312-3320
800-437-4010
OncologyClinicalTrialsFargo@sanfordhealth.org701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org701-234-6161
CancerTrials@EssentiaHealth.org218-786-3308
CTUReferral@UHhospitals.org800-641-2422
clinical.trials@daytonncorp.org937-528-2900
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
CTUReferral@UHhospitals.org800-641-2422
holly.henry@va.gov
Jamesline@osumc.edu800-293-5066
clinical.trials@daytonncorp.org937-528-2900
937-276-8320
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
937-569-7515
clinical.trials@daytonncorp.org937-528-2900
CTUReferral@UHhospitals.org800-641-2422
Roster@nrgoncology.org412-339-5294
405-752-3402
trials@ohsu.edu503-494-1080
800-949-1004
610-776-4714
484-503-4151
HemonCCTrials@geisinger.edu570-271-5251
Roster@nrgoncology.org412-339-5294
HemonCCTrials@geisinger.edu570-459-2901
HemonCCTrials@geisinger.edu570-374-8555
412-647-2811
HemonCCTrials@geisinger.edu800-275-6401
610-776-4714
HemonCCTrials@geisinger.edu570-703-4768
Roster@nrgoncology.org412-339-5294
HemonCCTrials@geisinger.edu570-271-5251
866-590-2976
kwade@bmhsc.org843-522-7819
ashley.salvo@va.gov843-789-7020
hcc-clinical-trials@musc.edu843-792-9321
kmertz-rivera@gibbscc.org864-560-6104
Kim.Williams3@prismahealth.org864-522-4317
kmertz-rivera@gibbscc.org864-560-6104
864-560-6812
kmertz-rivera@gibbscc.org864-560-6104
864-560-6812
kmertz-rivera@gibbscc.org864-560-6104
OncologyClinicTrialsSF@sanfordhealth.org605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org605-312-3320
BCCclintrials@bmhcc.org901-226-1366
877-469-5300
801-582-1565
Charmaine.A.Mckie@kp.org240-632-4285
Charmaine.A.Mckie@kp.org240-632-4285
ctoclinops@vcu.edu
CTOclinops@vcu.edu804-628-6430
540-981-7377
Charmaine.A.Mckie@kp.org240-632-4285
research@valleymed.org425-228-3440
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
Memorial-ClinicalTrials@yvmh.org509-574-3535
cancertrialsinfo@hsc.wvu.edu304-293-7374
cancertrialsinfo@hsc.wvu.edu304-293-7374
cancertrialsinfo@hsc.wvu.edu304-293-7374
cancertrialsinfo@hsc.wvu.edu304-293-7374
304-487-7515
304-243-6442
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
oncology.clinical.trials@marshfieldresearch.org800-782-8581
WI_research_admin@hshs.org920-433-8889
wi_research_admin@hshs.org920-433-8889
CancerTrials@EssentiaHealth.org218-786-3308
218-568-4416
oncologyclinicaltrials@mhemail.org608-756-6871
608-256-1901 ext. 17007
oncology.clinical.trials@marshfieldresearch.org800-782-8581
888-469-6614
oncology.clinical.trials@marshfieldresearch.org800-782-8581
mmcorc@healthpartners.com952-993-1517
oncology.clinical.trials@marshfieldresearch.org800-782-8581
CancerTrials@EssentiaHealth.org218-786-3308
oncology.clinical.trials@marshfieldresearch.org800-782-8581
701-364-6272
oncology.clinical.trials@marshfieldresearch.org800-782-8581
oncology.clinical.trials@marshfieldresearch.org800-782-8581
Roster@nrgoncology.org412-339-5294
research@billingsclinic.org800-996-2663
787-395-7085
787-780-2865
info@panoncologytrials.com787-407-3333
787-621-4397
marcia.cruzcorrea@panoncologytrials.com787-407-3333
info@panoncologytrials.com787-407-3333
787-274-3387
sajresearchcontactus@va.gov787-641-7582
Roster@nrgoncology.org412-339-5294
info@PRoncology.com787-919-7919
787-763-1296